Search Results for "Retin-A"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Retin-A. Results 61 to 70 of 72 total matches.
See also: tretinoin

Prevention and Treatment of Monkeypox

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
of monkeypox during an outbreak Cidofovir (Vistide) FDA-approved for treatment of cytomegalovirus retinitis ...
An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):137-9 |  Show IntroductionHide Introduction

Lasik and Its Alternatives: An Update

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004  (Issue 1174)
to the corneal endothelium, glaucoma, retinal detachment and cataract formation. CONCLUSION — LASIK, the most ...
Since the last Medical Letter article on surgical correction of refractive errors (Volume 41, page 122, 1999), some new techniques have been tried and new results have been reported.
Med Lett Drugs Ther. 2004 Jan 19;46(1174):5-7 |  Show IntroductionHide Introduction

ThermaClear for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007  (Issue 1263)
acnes, and retinoids such as tretinoin (Retin-A, and others), adapalene (Differin) and tazarotene ...
The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate inflammatory acne, not severe nodular or severe cystic acne, and it is not meant to be used on blackheads and whiteheads. Two similar devices are already on the market: Zeno, another handheld device that delivers heat to acne lesions, and the Radiancy Clear Touch Lite Acne Clearance System, a larger heat-delivery device.
Med Lett Drugs Ther. 2007 Jun 18;49(1263):51-2 |  Show IntroductionHide Introduction

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
every 1-4 months depending on disease activity. Conjunctival hemorrhage, endophthalmitis, retinal ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 |  Show IntroductionHide Introduction

Drugs for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
such as serous retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy can occur rarely ...
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Med Lett Drugs Ther. 2022 May 2;64(1649):65-9 |  Show IntroductionHide Introduction

Suvorexant (Belsomra) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
doses that were at least 7 times those used in humans found an increased incidence of retinal atrophy ...
The FDA has approved suvorexant (Belsomra – Merck), the first orexin receptor antagonist to become available in the US, for treatment of sleep-onset and/or sleep-maintenance insomnia.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):29-31 |  Show IntroductionHide Introduction

Drugs for Open-Angle Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
vision can occur. Retinal detachment can also occur, especially in highly myopic patients. Systemic ...
Glaucoma is a progressive optic neuropathy associated with increased intraocular pressure (IOP; normal range 8-22 mm Hg), which is the only disease-related factor that can be modified. Topical drugs that lower IOP are the first line of treatment for open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8   doi:10.58347/tml.2025.1727a |  Show IntroductionHide Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
; delirium; psychosis; vertigo; seizures; paresthesias; blurred vision and photophobia; retinal detachment ...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse...
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
with tamoxifen can increase the risk of retinal toxicity.6 Sulfasalazine – The aminosalicylate sulfasalazine ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for HIV Infection

   
Treatment Guidelines from The Medical Letter • Feb 01, 2014  (Issue 138)
resistance/diabetes; retinal changes; optic neuritis indinavir and atazanavir Emtricitabine Well tolerated ...
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Treat Guidel Med Lett. 2014 Feb;12(138):7-16 |  Show IntroductionHide Introduction